undamentalytics Newsletter
Sign in

Genelux Corp revenue

Genelux Corp's revenue was $8,000 in fiscal 2025, up 0.0% on the year before. Since fiscal 2022 ($11.1m) it has grown at a compound -91.0% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue11000
Growth on the year before—−98.5%−95.3%0.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Genelux Corp $8,000 -95.3% —
Creative Medical Technology Holdings, Inc. $3,000 -50.0% -65.6%
Lyell Immunopharma, Inc. $27,000 -55.0% -91.8%
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —

Compare with peers

Head to head: CELZ vs GNLXGNLX vs LYELAIM vs GNLX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Genelux Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Genelux Corp.